In the phase III HERO study (70), patients with advanced PCa (> 90% of whom had ≥ 1 CV risk factor, e.g. diabetes mellitus, hypertension, or a history of a MACE) were randomized to receive relugolix (an oral LHRH antagonist; N = 622) or leuprolide (an LHRH agonist; N = 308). The gene discussed is GNRH1; the disease is diabetes mellitus.